Spironolactone for Hair Loss in Women

Spironolactone is a prescription tablet, and dermatologists prescribe spironolactone off-label for androgenic alopecia — female-pattern hair loss — because of its ability to arrest hair loss progression and its long-term safety profile. FDA labeling for spironolactone lists its approved indications as heart failure, high blood pressure, edema, and primary hyperaldosteronism, and the only two drugs approved by the FDA for androgenetic alopecia are finasteride and minoxidil — which is why prescribing spironolactone for hair is off-label. Spironolactone is taken as a daily tablet, and it carries one rule that isn't a suggestion: FDA labeling for spironolactone directs prescribers to avoid spironolactone in pregnant women. Whether spironolactone fits you is a decision a medical provider licensed in your state makes after reviewing your health history.

Here's the honest version of what spironolactone is, how it's used for hair, and the fine print that actually matters — with every claim traceable to an FDA label or the published literature.

First, what "off-label" really means

You'll see "off-label" attached to several women's hair treatments, so it's worth understanding rather than fearing. Off-label means a medication is FDA-approved for one condition and prescribed for another, based on a provider's clinical judgment. It is legal, it is common, and it happens throughout everyday medicine.

Spironolactone is a clear example. FDA labeling for spironolactone lists its indications as NYHA Class III-IV heart failure, add-on therapy for hypertension, edema in cirrhosis and nephrotic syndrome, and primary hyperaldosteronism. None of those is hair loss — and yet spironolactone has been widely used by dermatologists to treat androgenetic alopecia, and the Cochrane review of female pattern hair loss names spironolactone among the "widely-used treatments" in the field.

What off-label does not mean is "experimental" or "unregulated." Spironolactone has been used in medicine long enough to have a long-term safety profile, and spironolactone's behavior in the body is described in detail in its FDA labeling. When Ladies First lists a treatment as off-label, we say so plainly, right on the option — so you're never surprised by what you're taking or why. What off-label does mean is that spironolactone has never been through an FDA review for hair loss specifically, so the evidence behind it looks different from the evidence behind an approved drug. We get into exactly how below.

How spironolactone is used for hair

Androgenetic alopecia is mediated by genetic predisposition and excessive follicular sensitivity to androgens, which progressively converts scalp terminal hair into vellus hair — thick, long hairs turning fine and short. Female pattern hair loss is characterised by progressive shortening of the hair's growth phase and progressive follicular miniaturisation. Androgens are a group of hormones everyone has; the issue in female-pattern hair loss is how susceptible your follicles are to them.

Spironolactone pushes back on that signal. FDA labeling for spironolactone refers to the anti-androgenic properties of spironolactone, and spironolactone is a synthetic aldosterone receptor antagonist known to stimulate hair growth. Prescribed for hair, spironolactone is used to blunt androgen activity so susceptible follicles are under less pressure to miniaturize.

Spironolactone works better with company. Spironolactone showed better efficacy for androgenetic alopecia in combination with other therapies such as oral or topical minoxidil than as monotherapy. Topical minoxidil is FDA-labeled as a hair regrowth treatment for women, and the Cochrane review found evidence supporting the efficacy and safety of topical minoxidil in female pattern hair loss — so spironolactone is typically added to minoxidil, not swapped for it.

On dose, the honest answer is that it varies and your provider sets it. Across the studies in a systematic review of spironolactone for androgenetic alopecia, oral spironolactone doses ranged from 25 mg to 200 mg daily, with the vast majority between 80 mg and 110 mg. A randomized trial used oral spironolactone 80-100 mg daily alongside 5% topical minoxidil. Consistency matters more than any single dose. You can see spironolactone beside every other treatment, with honest notes and real prices, on our Women's Hair Loss page.

What the evidence does and doesn't show

This is where we'd rather be straight with you than sell you. The strongest single piece of evidence for spironolactone in women's hair loss is a randomized trial: in 120 women with female pattern hair loss, 5% topical minoxidil plus oral spironolactone increased hair density significantly more than 5% topical minoxidil alone at week 24 (p = 0.009). That is a real, measured benefit from adding spironolactone.

But the same trial is honest about the trade-offs, and so are we. In that trial the minoxidil-plus-spironolactone group had the most reported adverse effects, and minoxidil combined with microneedling outperformed minoxidil plus spironolactone on hair density. Spironolactone is one good option, not the best option for everyone.

And the evidence base overall is thinner than you might expect for a drug this widely used. A systematic review of spironolactone for androgenetic alopecia found only 7 qualifying studies covering 618 patients, and concluded that more high-quality randomized controlled studies should be performed. The Cochrane review of female pattern hair loss concluded that further randomised controlled trials of widely-used treatments such as spironolactone are needed. That is the honest reason spironolactone remains off-label: not that it's suspect, but that it has never been put through the trial program an FDA approval requires.

So we frame spironolactone the way the science supports: as a reasonable, provider-directed option, not a guarantee. Here is the closest thing to a real answer on what to expect. In a study of 80 women with female pattern hair loss treated for a minimum of 12 months with oral antiandrogens — 40 of them on spironolactone 200 mg daily — 44% had hair regrowth, 44% had no clear change in hair density, and 12% experienced continuing hair loss. Put the other way: 88% of the women receiving oral antiandrogens could expect to see no progression of their hair loss, or improvement. Note what that means — for nearly half, success looked like holding steady. In hair medicine, keeping what you have is itself a win. (Those results combined spironolactone with cyproterone acetate, and the authors noted a placebo-controlled study is still required — which is exactly the limitation we just described.)

The pregnancy rule — and it's a hard one

This is the part that isn't a suggestion. FDA labeling for spironolactone states that, based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis. The labeling directs prescribers to avoid spironolactone in pregnant women, or to advise a pregnant woman of the potential risk to a male fetus, because of the anti-androgenic properties of spironolactone. Rat embryofetal studies reported feminization of male fetuses and endocrine dysfunction in females exposed to spironolactone in utero. That is the specific, labeled concern — an anti-androgen acting on a developing male fetus.

A medical provider licensed in your state screens for pregnancy and family planning during your consult, every time. This screening is not a formality. If you are pregnant, trying to conceive, or breastfeeding, tell your provider — it changes the recommendation, and your provider will steer you toward a different option.

The other honest notes

Beyond pregnancy, spironolactone has a few labeled effects worth knowing before you start — all of which are why spironolactone is prescription-only and provider-monitored:

Potassium. FDA labeling for spironolactone states that spironolactone can cause hyperkalemia — high potassium — and directs monitoring of serum potassium within one week of starting or adjusting spironolactone, and regularly thereafter. This follows from how the drug works: FDA labeling for spironolactone states that spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. The labeling notes this risk is increased by impaired renal function or by potassium supplements and drugs that raise potassium, such as ACE inhibitors and ARBs — which is why your provider asks about every medication and supplement you take. Reassuringly, at the low doses used for hair: in a pilot study of 100 women taking spironolactone 25 mg with oral minoxidil, no patients developed hyperkalemia or any other blood test abnormality.

Blood pressure and lightheadedness. FDA labeling for spironolactone warns that excessive diuresis may cause symptomatic dehydration, hypotension, and worsening renal function, and lists dizziness, lethargy, headache, and drowsiness among reported adverse reactions to spironolactone. Spironolactone is a diuretic by design, so more frequent urination is part of the deal.

Menstrual changes and breast tenderness. FDA labeling for spironolactone lists irregular menses or amenorrhea, postmenopausal bleeding, and breast and nipple pain among reported adverse reactions to spironolactone. These are worth reporting to your provider.

Who shouldn't take it at all. FDA labeling for spironolactone lists three contraindications: hyperkalemia, Addison's disease, and concomitant use of eplerenone.

None of this is meant to alarm you — it's meant to be the conversation you'd want to have before taking any prescription. It's the same kind of careful screening we describe for other prescription treatments in Are Semaglutides Safe. The point of provider oversight is that someone qualified is watching for these things with you.

The timeline: think in months, and think in years

Hair treatments ask for patience, and spironolactone is no exception. The studies tell you what the mirror won't. In a pilot study of 100 women on oral minoxidil 0.25 mg plus spironolactone 25 mg daily, the mean reduction in hair loss severity score was 0.85 at 6 months and 1.3 at 12 months — the benefit was still growing between month six and month twelve. The randomized trial of minoxidil plus spironolactone measured its results at week 24, and the study of oral antiandrogens photographed women only after a minimum of 12 months of therapy. Six months is roughly when there's something to judge; twelve months is when you know. Take a photo of your part in the same light once a month, because real change is too gradual to see day to day.

And the truth about stopping: spironolactone manages a condition, it does not cure it. The clearest labeled statement on this point comes from the other half of the regimen — FDA labeling for topical minoxidil directs that continued use of minoxidil is necessary to increase and keep hair regrowth, or hair loss will begin again. Prolonged use of the FDA-approved androgenetic alopecia drugs is likewise a prerequisite for enhanced treatment response, and dermatologists use spironolactone off-label for androgenic alopecia because of spironolactone's ability to arrest hair loss progression — a job spironolactone can only do while you are taking spironolactone. The studies that measured spironolactone's benefit kept women on daily therapy for 12 months and longer. Treat spironolactone as an ongoing plan, and talk to your provider before stopping.

Is it right for you?

Spironolactone is one tool among several, and spironolactone isn't the automatic answer for everyone. Spironolactone showed better efficacy for androgenetic alopecia in combination with oral or topical minoxidil than as monotherapy. FDA labeling for spironolactone directs prescribers to avoid spironolactone in pregnant women. And in a randomized trial of 120 women with female pattern hair loss, 5% topical minoxidil plus microneedling increased hair density more than 5% topical minoxidil plus oral spironolactone at week 24. Spironolactone works best as part of a plan a provider builds around your specific situation. You can see spironolactone alongside every other option — topical and oral, with honest notes and real prices — on our Women's Hair Loss page.

If you're still sorting out why your hair is thinning in the first place, start with Women's Hair Loss: Why It Happens, then let a provider take it from there.

The way to find out whether spironolactone fits your health is a medical evaluation, not an article. It takes a few minutes online to start, costs nothing, and nothing is prescribed or charged until a medical provider licensed in your state reviews your health history.

See if it fits your health. Answer a few questions online — it takes a few minutes, costs nothing, and a medical provider licensed in your state reviews everything, usually within 48 hours. You're never charged unless a provider approves your plan.

Questions women actually ask

Sources

1. FDA labeling (DailyMed) — Spironolactone tablets: Indications and Usage; Contraindications; Warnings and Precautions (Hyperkalemia; Hypotension and Worsening Renal Function); Adverse Reactions; Use in Specific Populations (Pregnancy; Lactation); Mechanism of Action.
2. FDA labeling (DailyMed) — Minoxidil (for Women) topical foam: Purpose, Use, and Directions.
3. FDA labeling (DailyMed) — Dutasteride capsules: Indications and Usage; Contraindications.
4. Wei C, et al. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol. 2020;83(4):1021-1027. PMID 32446820.
5. van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;(5):CD007628. PMID 27225981.
6. Wang C, et al. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Clin Cosmet Investig Dermatol. 2023;16:603-612. PMID 36923692.
7. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466-473. PMID 15787815.
8. Liang X, et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med. 2022;9:905140. PMID 35899211.
9. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109. PMID 29231239.
10. Ntshingila S, et al. Androgenetic alopecia: An update. JAAD Int. 2023;13:150-158. PMID 37823040.